Peptic ulcer refers to the group of gastrointestinal disorders such as gastritis, gastric ulcers, and Duodenal ulcers or gastroesophageal reflux disease (GERD). Drugs used for the treatment of peptic ulcers include those that reduce gastric ulcer secretion, such as PPI and H2 receptor antagonists and acid neutralization agents such as antacids and antibiotics against H. pylori infection. However, these drugs are often used in combination for effective treatment.
Find Out More about the Report Coverage
- Pfizer Inc.
- Abbvie Inc.
- GlaxoSmithKline plc.
- AstraZeneca plc
- Boehringer Ingelheim GmbH
- Daewoong Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical
- Eisai Co. Ltd.
- Cadila Healthcare Ltd.
- Yuhan Corporation
Peptic Ulcer Drugs Market Trends
Factors driving the growth of the global peptic ulcer drugs market include growing prevalence of peptic ulcers, increasing adoption of peptic ulcer drugs over surgery, R&D stimulation through government policies, increasing number of generic manufacturers of peptic ulcer drugs, changes in disease management, etc.
Furthermore, factors such as growing prevalence of stress-induced ulcers due to changing lifestyle and diet, increasing smoking rate, and progressive population of geriatrics are anticipated to promote the expansion of the global peptic ulcer drugs market size over the forecast period of 2020 to 2030.
However, the side effects of peptic ulcer drugs, poor pipeline productivity, and changes in pricing policies of drugs are factors expected to hamper the growth of the global peptic ulcer drugs market over the coming years.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Regional Analysis of Peptic Ulcer Drugs Market
North America led the global peptic ulcer drugs market share in 2019, and this trend is projected to continue over the forecast period too, with the region expected to hold a share of 41.5% of the global market in 2020.
Surge in the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and growing awareness regarding the treatment options for peptic ulcers are factors expected to drive the growth of the peptic ulcer drugs market in the North American region.
The peptic ulcer drugs market in Europe accounts for the second-largest share, primarily due to easy availability of successful treatment options for peptic ulcers in the region.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Peptic Ulcer Drugs Market Competition
Top players in the global peptic ulcer drugs market covered in this report are Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Abbott Laboratories, AstraZeneca plc., Cadila Healthcare Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and GlaxoSmithKline Plc., among others.
Explore Persistence Market Research’s expertise in promulgation of the business !
COVID-19 Impact on Peptic Ulcer Drugs Market
The most unprecedented operational and economic challenges have emerged owing to the ongoing COVID-19 pandemic - an acute respiratory distress syndrome caused by the novel coronavirus. In addition, a significant period of time is required for the development and commercialization of effective treatment options for this new pathogen of COVID-19.
These collective challenges of infection transmission and treatment are estimated to delay the diagnosis and treatment of GI-disease in the coming quarters of 2020 and 2021. Reduced physician and hospital visits for non-essential health issues due to the prioritization of COVID-19 treatment will impede market growth.
The peptic ulcer drugs market is expected to recover to pre-pandemic market demand in 2021, owing to the availability of COVID-19 vaccinations. This will reflect in terms of the recovery of developed and emerging economies from the COVID-19 pandemic.
In addition, local governments are prioritizing healthcare resources to tackle COVID-19 challenges, which is also expected to slow down the progress of the peptic ulcer drugs market in the short term.
Growth of the global peptic ulcer drugs market will be led by the North America region throughout the forecast period of 2020 to 2030, followed by Europe and East Asia. Stakeholders in the peptic ulcer drugs market space can look to these regions for increased profits and growing their market share. Overall, the global market is set to expand 1.3X over the next ten years.
Key Segments of Peptic Ulcer Drugs Market
PMR’s study on the peptic ulcer drugs market offers information divided into four important segments—product, indication, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Questions Answered in PMR’s Peptic Ulcer Drugs Market Report
- Which regions will continue to remain the most profitable regional markets for peptic ulcer drugs market players?
- Which factors will induce a change in the demand for peptic ulcer drugs during the assessment period?
- What are the different opportunities available for emerging players in the peptic ulcer drugs market?
- How are supply-side and demand-side drivers impacting the peptic ulcer drugs market?
- How will changing trends impact the peptic ulcer drugs market?
- How can market players capture the low-hanging opportunities in the peptic ulcer drugs market in developed regions?
- Which companies are leading the peptic ulcer drugs market?
- What are the winning strategies of stakeholders in the peptic ulcer drugs market to upscale their position in this landscape?